Bio-Techne Stock (NASDAQ:TECH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$66.37

52W Range

$61.16 - $85.57

50D Avg

$73.97

200D Avg

$73.61

Market Cap

$10.92B

Avg Vol (3M)

$906.89K

Beta

1.28

Div Yield

$0.32 (0.47%)

TECH Company Profile


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3,100

IPO Date

Feb 09, 1989

Website

TECH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Jun 23
Royalty$23.34M$21.10M
Consumables$928.18M$917.73M
Instruments$108.27M$112.08M

Fiscal year ends in Jun 24 | Currency in USD

TECH Financial Summary


Jun 24Jun 23Jun 22
Revenue$1.16B$1.14B$1.11B
Operating Income$206.69M$298.94M$296.59M
Net Income$168.10M$285.26M$272.05M
EBITDA$318.40M$406.18M$397.66M
Basic EPS$1.07$1.81$1.73
Diluted EPS$1.05$1.76$1.66

Fiscal year ends in Jun 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25Oct 30, 24 | 3:48 PM
Q4 24Aug 07, 24 | 3:03 PM
Q3 24May 01, 24 | 12:20 PM

Peer Comparison


TickerCompany
NUVLNuvalent, Inc.
AKROAkero Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
EXELExelixis, Inc.
HALOHalozyme Therapeutics, Inc.
VTYXVentyx Biosciences, Inc.
BGNEBeiGene, Ltd.
BMRNBioMarin Pharmaceutical Inc.
TVTXTravere Therapeutics, Inc.
ALNYAlnylam Pharmaceuticals, Inc.
REPLReplimune Group, Inc.
LEGNLegend Biotech Corporation
ASNDAscendis Pharma A/S
LQDALiquidia Corporation
PCVXVaxcyte, Inc.
UTHRUnited Therapeutics Corporation